• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evaluation of microRNA-205 expression as a potential triage marker for patients with low-grade squamous intraepithelial lesions.评估微小RNA-205表达作为低级别鳞状上皮内病变患者潜在分诊标志物的价值。
Oncol Lett. 2017 May;13(5):3586-3598. doi: 10.3892/ol.2017.5909. Epub 2017 Mar 24.
2
3
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.有关人乳头瘤病毒检测在宫颈癌二级预防中的证据。
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095.
4
Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.应用 Onclarity HPV 扩展基因分型检测技术对≥21 岁的 ASC-US 或 LSIL 细胞学检查结果的女性进行高级别宫颈疾病的风险检测。
Gynecol Oncol. 2019 Aug;154(2):360-367. doi: 10.1016/j.ygyno.2019.05.012. Epub 2019 May 31.
5
The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.HPV16 和 HPV18 基因分型以及细胞学检测在基于 HPV 筛查的自我采样样本分流中不同阈值的效果比较。
PLoS One. 2020 Jun 11;15(6):e0234518. doi: 10.1371/journal.pone.0234518. eCollection 2020.
6
Liquid-based cytology with HPV triage of low-grade cytological abnormalities versus conventional cytology in cervical cancer screening.液基细胞学联合 HPV 分流检测在宫颈癌筛查中用于处理低级别细胞学异常与传统巴氏涂片的比较。
Curr Pharm Des. 2013;19(8):1406-11.
7
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS).预测阴道镜检查后随访期间CIN3的绝对风险:非典型鳞状细胞意义不明确/低度鳞状上皮内病变分流研究(ALTS)的结果
Am J Obstet Gynecol. 2006 Aug;195(2):341-8. doi: 10.1016/j.ajog.2006.02.047.
8
Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group.人乳头瘤病毒检测用于对有低度鳞状上皮内病变细胞学证据的女性进行分流:一项随机试验的基线数据。意义不明确的非典型鳞状细胞/低度鳞状上皮内病变分流研究(ALTS)组。
J Natl Cancer Inst. 2000 Mar 1;92(5):397-402. doi: 10.1093/jnci/92.5.397.
9
Management of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions of the uterine cervix with human papilloma virus infection among young women aged less than 25 years.25岁以下感染人乳头瘤病毒的年轻女性子宫颈意义不明确的非典型鳞状细胞或低级别鳞状上皮内病变的管理
Diagn Cytopathol. 2016 Dec;44(12):959-963. doi: 10.1002/dc.23533. Epub 2016 Oct 7.
10
Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.与细胞学检查相比,高危型人乳头瘤病毒(HPV)DNA基因分型用于原发性宫颈癌筛查及HPV阳性女性分流的诊断准确性:PIPAVIR研究的初步结果
Arch Gynecol Obstet. 2017 May;295(5):1247-1257. doi: 10.1007/s00404-017-4324-x. Epub 2017 Mar 23.

引用本文的文献

1
Cervical Cancer, Papillomavirus, and miRNA Dysfunction.宫颈癌、乳头瘤病毒与微小RNA功能障碍
Front Mol Biosci. 2021 Dec 10;8:758337. doi: 10.3389/fmolb.2021.758337. eCollection 2021.
2
Role of microRNAs as biomarkers of cervical carcinogenesis: a systematic review.微小RNA作为宫颈癌发生生物标志物的作用:一项系统综述。
Obstet Gynecol Sci. 2021 Sep;64(5):419-436. doi: 10.5468/ogs.21123. Epub 2021 Aug 13.
3
MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy.液体活检中高级别宫颈上皮内瘤变的 microRNA 生物标志物。
Biomed Res Int. 2021 Apr 13;2021:6650966. doi: 10.1155/2021/6650966. eCollection 2021.
4
Identification of Circulating MicroRNAs as a Promising Diagnostic Biomarker for Cervical Intraepithelial Neoplasia and Early Cancer: A Meta-Analysis.循环 microRNAs 作为一种有前途的宫颈上皮内瘤变和早期癌症诊断生物标志物的鉴定:一项荟萃分析。
Biomed Res Int. 2020 Mar 23;2020:4947381. doi: 10.1155/2020/4947381. eCollection 2020.
5
Human Papillomavirus Infections, Cervical Cancer and MicroRNAs: An Overview and Implications for Public Health.人乳头瘤病毒感染、宫颈癌与 microRNAs:综述及对公共卫生的影响。
Microrna. 2020;9(3):174-186. doi: 10.2174/2211536608666191026115045.

本文引用的文献

1
Current State of Circulating MicroRNAs as Cancer Biomarkers.循环微RNA作为癌症生物标志物的现状
Clin Chem. 2015 Sep;61(9):1138-55. doi: 10.1373/clinchem.2015.241190. Epub 2015 Aug 3.
2
Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer.循环微RNA-203可预测人类胃癌的转移、早期复发及不良预后。
Gastric Cancer. 2016 Jul;19(3):744-53. doi: 10.1007/s10120-015-0521-0. Epub 2015 Aug 2.
3
Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.血清微小RNA-205的下调作为人类胶质瘤潜在的诊断和预后生物标志物
J Neurosurg. 2016 Jan;124(1):122-8. doi: 10.3171/2015.1.JNS141577. Epub 2015 Jul 31.
4
Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer.血清miR-372是早期结直肠癌患者的诊断和预后生物标志物。
Anticancer Agents Med Chem. 2016;16(4):424-31. doi: 10.2174/1871520615666150716110406.
5
MicroRNAs May Serve as Emerging Molecular Biomarkers for Diagnosis and Prognostic Assessment or as Targets for Therapy in Gastric Cancer.微小RNA可能成为胃癌诊断和预后评估的新兴分子生物标志物,或作为胃癌治疗的靶点。
Asian Pac J Cancer Prev. 2015;16(12):4813-20. doi: 10.7314/apjcp.2015.16.12.4813.
6
Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer.循环miR-103和miR-720作为结直肠癌患者新的血清生物标志物。
Int J Oncol. 2015 Sep;47(3):1097-102. doi: 10.3892/ijo.2015.3064. Epub 2015 Jun 26.
7
Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer.循环微RNA——乳腺癌分子诊断的新前沿。
Genes Cancer. 2015 May;6(5-6):281-7. doi: 10.18632/genesandcancer.66.
8
A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.血清 microRNA 分类器用于早期检测肝细胞癌:一项具有巢式病例对照研究的多中心、回顾性、纵向生物标志物识别研究。
Lancet Oncol. 2015 Jul;16(7):804-15. doi: 10.1016/S1470-2045(15)00048-0. Epub 2015 Jun 15.
9
Let-7c is a Candidate Biomarker for Cervical Intraepithelial Lesions: A Pilot Study.
Mol Diagn Ther. 2015 Jun;19(3):191-6. doi: 10.1007/s40291-015-0145-4.
10
Serum microRNA-205 as a novel biomarker for cervical cancer patients.血清 microRNA-205 作为宫颈癌患者的新型生物标志物。
Cancer Cell Int. 2014 Aug 22;14:81. doi: 10.1186/s12935-014-0081-0. eCollection 2014.

评估微小RNA-205表达作为低级别鳞状上皮内病变患者潜在分诊标志物的价值。

Evaluation of microRNA-205 expression as a potential triage marker for patients with low-grade squamous intraepithelial lesions.

作者信息

Xie Hong, Norman Ingrid, Hjerpe Anders, Vladic Tomislav, Larsson Catharina, Lui Weng-Onn, Östensson Ellinor, Andersson Sonia

机构信息

Tianjin Life Science Research Center and Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, P.R. China.

Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.

出版信息

Oncol Lett. 2017 May;13(5):3586-3598. doi: 10.3892/ol.2017.5909. Epub 2017 Mar 24.

DOI:10.3892/ol.2017.5909
PMID:28529583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5431461/
Abstract

High-risk human papillomavirus (HPV) testing is a recommended triage approach for females with atypical squamous cells of undetermined significance (ASCUS), but due to its poor specificity this approach is not recommended for patients with low-grade squamous intraepithelial lesions (LSIL). The objective of the current study was to determine microRNA (miR)-205 expression levels in liquid-based cytology (LBC) samples, and evaluate their ability to predict cervical intraepithelial neoplasia grade 2/3 or worse (CIN2/3+) in females with minor cytological abnormalities. LBC samples were obtained from patients attending the Swedish Cervical Cancer Screening Program. The Mann-Whitney U test, one-way analysis of variance, Kruskal-Wallis test, Spearman rank order correlation analysis, and Pearson's χ test were used to assess the results. Accuracy analyses indicated that high miR-205 expression had a significantly higher specificity to high-risk HPV testing, and a sensitivity similar to that of high-risk HPV testing to predict CIN2+ and CIN3+ in women with LSIL, but not those with high-grade squamous intraepithelial lesions. Although further research is required for females with LSIL, miR-205 expression in LBC samples may be a novel triage marker for, or a beneficial supplement to high-risk-HPV testing in these patients.

摘要

高危型人乳头瘤病毒(HPV)检测是对意义不明确的非典型鳞状细胞(ASCUS)女性推荐的分流方法,但由于其特异性较差,该方法不推荐用于低级别鳞状上皮内病变(LSIL)患者。本研究的目的是确定液基细胞学(LBC)样本中微小RNA(miR)-205的表达水平,并评估其预测轻度细胞学异常女性宫颈上皮内瘤变2/3级或更严重病变(CIN2/3+)的能力。LBC样本取自参加瑞典宫颈癌筛查项目的患者。采用曼-惠特尼U检验、单因素方差分析、Kruskal-Wallis检验、Spearman等级相关分析和Pearson卡方检验来评估结果。准确性分析表明,高miR-205表达对高危型HPV检测具有显著更高的特异性,在预测LSIL女性的CIN2+和CIN3+方面具有与高危型HPV检测相似的敏感性,但对高级别鳞状上皮内病变女性则不然。尽管对LSIL女性还需要进一步研究,但LBC样本中miR-205表达可能是这些患者高危型HPV检测的一种新型分流标志物或有益补充。